Skip to main content

Characteristics and Rates of Diabetic Ketoacidosis (DKA) by Chronic Kidney Disease (CKD) Stage Among Patients with Short/Rapid-Acting Insulin Use and Type 1 Diabetes Mellitus (T1DM): A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
short/rapid-acting insulin
Health Outcome(s)
diabetic ketoacidosis
Description

In this report, we described characteristics of individuals with dispensings of short/rapid-acting insulin and a history of type 1 diabetes mellitus (T1DM) in the Sentinel Distributed Database (SDD). Among these cohorts, we assessed occurrence of diabetic ketoacidosis (DKA) by chronic kidney disease (CKD) stage and calculated incidence rates.

The study period includes data from March 1, 2013 to February 29, 2024. We distributed this request to six Sentinel Data Partners on September 10, 2024.

Deliverables (1)
Sentinel Modular Program Report: Characteristics and Rates of Diabetic Ketoacidosis (DKA) by Chronic Kidney Disease (CKD) Stage Among Patients with Short/Rapid-Acting Insulin Use and Type 1 Diabetes Mellitus (T1DM): A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
March 1, 2013 - February 29, 2024
Analysis Type
Descriptive
Population / Cohort
All individuals with type 1 diabetes mellitus
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Chronic Kidney Disease (CKD) Stage & Diabetic Ketoacidosis (DKA) and Use in Type 1 Diabetes Mellitus (T1DM)